Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Microsoft introduced a new video series that teaches Java developers how to build generative AI applications using modern ...

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...

Recursion Pharmaceuticals (RXRX) closed at $5.91 in the latest trading session, marking a -6.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.23% for the ...

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...